Skip to main content

Table 2 Frequency of prescriptions of single psychotropic substances

From: Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP

%

1994 - 1997

1998 – 2001

2002 – 2005

2006 - 2009

Overall

N

248

454

711

832

2246

Lithium

2.4 + 42.3

2.9 + 33.5

1.8 + 28.7

1.2 + 33.1

1.9 + 32.8

SSRI overall

2.4 + 15.3

3.5 + 22.4

2.4 + 29

2.0 + 28.6

2.5 + 26.0

Valproic acid

0.4 + 4.8

1.8 + 19.8

1.5 + 28.4

1.3 + 24.4

1.4 + 22.8

Mirtazapine

3.2

2.6 + 12.1

2.1 + 20.7

2.0 + 18.8

2.0 + 16.3

Venlafaxine

2.0 + 4.4

1.1 + 10.4

1.3 + 21.5

1.1 + 18.3

1.2 + 16.2

Quetiapine

 

0.7

0.3 + 12.7

1.4 + 28.1

0.6 + 14.6

Lamotrigine

 

0.7 + 2.9

0.1 + 17.7

0.4 + 22.2

0.3 + 14.4

Olanzapine

0.4

0.9 + 9.5

0.7 + 18

1.1 + 13.6

0.8 + 12.7

Carbamazepine

2.0 + 21

1.8 + 18.7

0.4 + 10.4

0.2 + 5.5

0.8 + 11.4

Escitalopram

  

0.7 + 10.1

1.1 + 14.4

0.6 + 8.5

Citalopram

0.8 + 4.8

1.3 + 8.1

0.8 + 9.8

0.2 + 7

0.7 + 7.9

Risperidone

1.6

0.2 + 5.9

0.1 + 7.3

0.2 + 7.6

0.2 + 6.5

Sertraline

0.4

0.9 + 6.4

0.4 + 5.1

0.5 + 4.0

0.5 + 4.4

Paroxetine

0.8 + 8.5

1.3 + 5.3

0.1 + 2.5

2.4

0.4 + 3.7

Perazine

0.8 + 5.6

0.4 + 5.3

3.1

1.3

0.2 + 3.2

Reboxetine

 

1.1 + 2.9

0.1 + 4.2

0.2 + 3.0

0.4 + 3.0

Haloperidol

0.8 + 11.3

0.4 + 4.0

1.5

0.7 + 1.3

0.4 + 3.0

Duloxetine

  

0.1 + 1.5

0.1 + 6.6

0.1 + 2.9

Melperone

2.0

0.2 + 3.3

0.4 + 3.7

2.4

0.2 + 2.9

Promethazine

0.8 + 5.6

0.2 + 3.1

0.1 + 1.4

0.5 + 1.7

0.4 + 2.3

Aripiprazole

  

1.5

0.1 + 4.7

2.0

Clozapine

3.2

0.2 + 2.2

0.3 + 1.7

0.1 + 1.8

0.2 + 2.0

Fluoxetine

0.8 + 1.6

2.6

0.4 + 1.5

0.2 + 0.8

0.3 + 1.5

  1. Table 2: Monotherapy (small numbers) and combination therapy (fat numbers) in percent (%) of all patients per time period. The substances are listed according to their frequency of prescription, with the most often prescribed substance listed first. Substances with overall prescription rates below 1.5% are not presented. Year of licensing in the respective countries: lamotrigine: epilepsy 1994, long term bipolar depression 2003; olanzapine: schizophrenia 1996, long term mania 2003; quetiapine: schizophrenia 2000, mania 2004, bipolar depression 2009.
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us